An overview of vaccinations in HIV

Current HIV/AIDS Reports

Volumn 4, Issue 3, 2007, Pages 105-113

  Overton, Edgar Turner ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIRETROVIRUS AGENT; CPG 7909; DIPHTHERIA VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS A HEPATITIS B VACCINE; HEPATITIS A VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOSUPPRESSIVE AGENT; INFLUENZA VACCINE; LIVE VACCINE; MEASLES MUMPS RUBELLA VACCINE; MENINGOCOCCUS VACCINE; PERTUSSIS VACCINE; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; SMALLPOX VACCINE; TETANUS TOXOID; TRIPLE VACCINE; VARICELLA ZOSTER VACCINE; WART VIRUS VACCINE;

ADJUVANT THERAPY; ANTIBIOTIC RESISTANCE; CD4 LYMPHOCYTE COUNT; CHICKENPOX; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIPHTHERIA; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG RESEARCH; DRUG SAFETY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INFLUENZA; MEASLES; MENINGOCOCCOSIS; MORTALITY; MUMPS; PATIENT CARE; PERTUSSIS; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; RUBELLA; SINGLE DRUG DOSE; SMALLPOX; STREPTOCOCCUS INFECTION; TETANUS; TREATMENT RESPONSE; VACCINATION; VIREMIA; VIRUS TRANSMISSION;

ADULT; AIDS VACCINES; HEPATITIS B; HEPATITIS B VACCINES; HIV INFECTIONS; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; PNEUMOCOCCAL VACCINES; PNEUMONIA;

EID: 34848884832     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-007-0016-7     Document Type: Review

References (49)

1. Campos M, Godson DL: The effectiveness and limitations of immune memory: understanding protective immune responses. International J Parasitol 2003, 33:655-661.
2. Egea E, Iglesias A, Salazar M, et al.: The cellular basis for lack of antibody response to hepatitis B vaccine in humans. J Exp Med 1991, 173:531-538.
3. Valdez H, Smith KY, Landay A, et al.: Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen. ACTG 375 team. AIDS Clinical Trials Group. AIDS 2000, 14:11-21.
4. Lane HC, Masur H, Edgar LC, et al.: Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engt J Med 1983, 309:453-458.
5. Glenney AT, Pope CG, Waddington H, et al.: XXIH-the antigenic value of toxoid precipitation by potassium alum. J Pathol Bacteriol 1926, 29:38-39.
6. Baylor NW, Egan W, Richman P: Aluminum salts in vaccines-US perspective. Vaccine 2002, 20:S18-23.
7. •• Chabalgoity JA, Baz A, Rial A, Grille S: The relevance of cytokines for development of protective immunity and rational design of vaccines. Cytokine Growth Factor Rev 2007, 18:195-207. A review of the cytokine involvement in generatin immune response.
8. Thio CL, Seaberg EC, Skolasky R J, et al.: HIV-1, hepatitis B, and risk of liver-related mortality in the Multicenter AIDS Cohort Study (MACS). Lancet 2002, 360:1921-1926.
9. • Laurence JC: Hepatitis A and B immunizations of individuals infected with human immunodeficiency virus. Am J Med 2005, 118(Suppl 10A):75S-83S. A concise review of HAV and HBV in patients with HIV infection with a focus on vaccines.
10. Recommendations of the Advisory Committee on Immunization Practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence. MMWR Recomm Rep 1993, 42:1-18.
11. Fonseca MO, Pang LW, de Paula Cavalheiro N, et al.: Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. Vaccine 2005, 23:2902-2908.
12. Overton ET, Sungkanuparph S, Powderly WG, et al.: Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons. Clin Infect Dis 2005, 41:1045-1048.
13. Sasaki M, Foccacia R, deMessias-Reason IJ: Efficacy of granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant for hepatitis B virus in patients with HIV infection. Vaccine 2003, 21:4545-4549.
14. • Cooper CL, Davis HL, Angel JB, et al.: CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. AIDS 2005, 19:1473-1479. A good example of potent adjuvant induction of immunity.
15. • Gandhi RT, Wurcel A, Lee H, et al.: Response to hepatitis B vaccine in HIV-1-positive subjects who test positive for isolated antibody to hepatitis B core antigen: implications for hepatitis B vaccine strategies. J Infect Dis 2005, 191:1435-1441. A clinical study addressing the common issue of isolated anti-HBc seropositivity.
16. Wallace MR, Brandt CJ, Earhart KC, et al.: Safety and immunogenicity of an inactivated hepatitis A vaccine among HIV-infected subjects. Clin Infect Dis 2004, 39:1207-1213.
17. Overton ET, Nurutdinova D, Sungkanuparph S, et al.: Predictors of immunity after hepatitis A vaccination in HIV-infected persons. J Viral Hepat 2007, 14:189-193.
18. Vento S, Garofano T, Renzini C, et al.: Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998, 338:286-290.
19. Lin JC, Nichol KL: Excess mortality due to pneumonia or influenza during influenza seasons among persons with acquired immunodeficiency syndrome. Arch Intern Med 2001, 161:441-446.
20. Sullivan PS, Hanson DL, Dworkin MS, et al.: Adult and Adolescent Spectrum of HIV Disease Investigators. Effect of influenza vaccination on disease progression among HIV-infected persons. AIDS 2000, 14:2781-2785.
21. Tasker SA, Treanor JJ, Paxton WB, Wallace MR: Efficacy of influenza vaccination in HIV-infected persons. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999, 131:430-433.
22. Yamanaka H, Teruya K, Tanaka M, et al.: HIV/Influenza Vaccine Study Team. Efficacy and immunologic responses to influenza vaccine in HIV-1-infected patients. J Acquir Immune Defic Syndr 2005, 39:167-173.
23. Fine AD, Bridges CB, De Guzman AM, et al.: Influenza A among patients with human immunodeficiency virus: an outbreak of infection at a residential facility in New York City. Clin Infect Dis 2001, 32:1784-1791.
24. Centers for Disease Control and Prevention: Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997, 46:1-24.
25. • Klugman KP, Madhi SA, Feldman C: HIV and pneumococcal disease. Curr Opin Infect Dis 2007, 20:11-15. A concise review of pneumococcal disease in patients with HIV infection with a focus on vaccines.
26. Flannery B, Schrag S, Bennett NM, et al.: Impact of childhood vaccination on racial disparities in invasive Streptococcus pneumoniae infections. JAMA 2004, 291:2197-2203.
27. Gebo KA, Moore RD, Keruly JC, Chaisson RE: Risk factors for pneumococcal disease in human immunodeficiency virus-infected patients. J Infect Dis 1996, 173:857-862.
28. Breiman RF, Keller DW, Phelan MA, et al.: Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients. Arch Intern Med 2000, 160:2633-2638.
29. • Watera C, Nakiyingi J, Miiro G, et al.: 23-valent pneumococcal polysaccharide vaccine in HIV-infected Ugandan adults: 6-year follow-up of a clinical trial cohort. AIDS 2004, 18:1210-1213. A clinical trial illustrating the difficulty of applying US treatment strategies in Africa.
30. Feikin DR, Elie CM, Goetz MB, et al.: Specificity of the antibody response to the pneumococcal polysaccharide and conjugate vaccines in human immunodeficiency virus-infected adults. Clin Diagn Lab Immunol 2004, 11:137-141.
31. Kroon FP, van Dissel JT, Ravensbergen E, et al.: Antibodies against pneumococcal polysaccharides after vaccination in HIV-infected individuals: 5-year follow-up of antibody concentrations. Vaccine 1999, 18:524-530.
32. Kurtzhals JA, Kjeldsen K, Heron I, Skinhoj P: Immunity against diphtheria and tetanus in human immunodeficiency virus-infected Danish men born 1950-1959. APMIS 1992, 100:803-808.
33. Chattopadhya D, Grover SS, Sharma M, et al.: Immune response in HIV-1-infected children with thalassaemia given a primary course of DPT vaccine before acquiring HIV-1 infection. Ann Trop Paediatr 2003, 23:279-292.
34. Stanley SK, Ostrowski MA, Justement JS, et al.: Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med 1996, 334:1222-1230.
35. Kroon FP, van Dissel JT, Labadie J, et al.: Antibody response to diphtheria, tetanus, and poliomyelitis vaccines in relation to the number of CD4+ T lymphocytes in adults infected with human immunodeficiency virus. Clin Infect Dis 1995, 21:1197-1203.
36. Bonetti TC, Succi RC, Weckx LY, et al.: Tetanus and diphtheria antibodies and response to a booster dose in Brazilian HIV-1-infected women. Vaccine 2004, 22:3707-3712.
37. Stephens DS, Hajjeh RA, Baughman WS, et al.: Sporadic meningococcal disease in adults: results of a 5-year population-based study. Ann Intern Med 1995, 123:937-940.
38. Kaplan LJ, Daum RS, Smaron M, McCarthy CA: Severe measles in immunocompromised patients. JAMA 1992, 267:1237-1241.
39. Wallace MR, Hooper DG, Graves SJ, Malone JL: Measles seroprevalence and vaccine response in HIV-infected adults. Vaccine 1994, 12:1222-1224.
40. Arpadi SM, Markowitz LE, Baughman AL, et al.: Measles antibody in vaccinated human immunodeficiency virus type 1-infected children. Pediatrics 1996, 97:653-657.
41. Krasinski K, Borkowsky W: Measles and measles immunity in children infected with human immunodeficiency virus. JAMA 1989, 261:2512-2516.
42. • Kancherla VS, Hanson IC: Mumps resurgence in the United States. J Allergy Clin Immunol 2006, 118:938-941. Epidemiologic evaluation of the recent mumps outbreak with a discussion of the impact of vaccine failure.
43. Madhi SA, Kuwanda L, Saarinen L, et al.: Immunogenicity and effectiveness of Haemophilus influenzae type B conjugate vaccine in HIV infected and uninfected African children. Vaccine 2005, 23:5517-5525.
44. • Oxman MN, Levin MJ, Johnson GR, et al.: A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005, 352:2271-2284. A clinical trial illustrating the efficacy of a vaccine to prevent zoster.
45. •• Palefsky JM, Gillison ML, Strickler HD: Chapter 16: HPV vaccines in immunocompromised women and men. Vaccine 2006, 24(Suppl 3):S140-146. A concise review of our state-of-knowledge regarding HPV and HIV, focusing on the role of HPV vaccines.
46. Tasker SA, Schnepf GA, Lim M, et al.: Unintended smallpox vaccination of HIV-1-infected individuals in the United States military. Clin Infect Dis 2004, 38:1320-1322.
47. Redfield RR, Wright DC, James WD, et al.: Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N Engl J Med 1987, 316:673-676.
48. Greenberg RN, Overton T, Haas DW, et al.: Safety and immunogenicity of Imvamune (MVA-BN) smallpox vaccine in HIV-infected subjects [abstract]. Paper presented at the 5th Annual ASM Biodefense and Emerging Disease Research Meeting. Washington, DC; February 27-March 2, 2007.
49. Kroger AT, Atkinson WL, Marcuse EK, et al.: General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006, 55:1-48.